66
Chapter 15 Anti-parkinsonism and anti- dementia drugs 抗抗抗抗抗抗抗抗抗抗抗抗

Chapter 15 Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

  • Upload
    hashim

  • View
    177

  • Download
    0

Embed Size (px)

DESCRIPTION

Chapter 15 Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药. Anti-Pakinsonism drugs. Muhammad Ali is known around the world as one of the great sports stars of the twentieth century. He needed great energy and power to become the world boxing champion. - PowerPoint PPT Presentation

Citation preview

Page 1: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Chapter 15

Anti-parkinsonism and anti-dementia drugs

抗帕金森病和老年性痴呆药

Page 2: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Anti-Pakinsonism drugs

Page 3: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Muhammad Ali is known around the world as one of the great sports stars of the twentieth century. He needed great energy and power to become the world boxing champion.

As he grew older, though, he began to change. The energy and power began to disappear. His face lost its expressiveness. His legs lost their speed.

Muhammad Ali is sixty-four now and long retired from boxing. Yet it was not age that changed him so much. It was Parkinson's disease.

Page 4: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Muhammad Ali and another celebrity with Parkinson's disease, actor Michael J. Fox, before the start of a Senate hearing on the disorder in 2002

Page 5: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

教皇保罗二世

希特勒

阿拉法特

邓小平

陈景润

Page 6: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

What is Parkinson’s disease?

A progressive nervous disease occurring most often after the age of 50, associated with the destruction of brain cells that produce dopamine, and characterized by muscular tremor, slowing of movement, partial facial paralysis, peculiarity of gait and posture, and weakness.

one of the “neurodegenerative diseases”

神经退行性疾病

Page 7: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

特征性症状 • rigidity 肌肉僵硬 • bradykinesia 运动徐缓• resting tremor 静止性震颤• abnormal postural reflexes 异常体位反射(姿态不稳)

Page 8: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

development in the past ten years about PD symptoms

deficits in the sense of smell;

fatigue;

disturbances of the autonomic nervous system which controls blood pressure, urinary bladder, bowel and sexual function;

sleep disorders;

a variety of behavioral features including anxiety and depression;

and finally neuropsychological abnormalities including dementia.

Page 9: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

中国 PD流行病学资料:

1986 0.047 %

2000 1.14 % (上海统计资料)

2006 2.0 % (全国统计资料)全国病人数 170 万

Page 10: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

发病率:

中国: 130 人 /10 万人

美国: 187 人 /10 万人

西北欧: 185 人 /10 万人

Mayo Clinic : lifetime risk of developing Parkinson's disease , 2 % for men and 1.3 % for women

Page 11: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

4000 年前有记载

1817,英国医师 James Parkinson首次报道

1953,确定病变部位在黑质

1960, Austria Hornykeiwicz 发现与黑质纹状体中 DA含量显著降低有关

80 % neurons loss in substantia nigra

利舍平( reserpine )耗竭 DA, 致 PD 症状

动物损毁 DA 通路,显相似症状

1961,用 L-dopa治疗取得良好的效果

Page 12: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

1997 年确定 4月 11 日

World Parkinson’s Disease Day

世界帕金森病日

纪念 James Parkinson 生日

Page 14: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Causes: why only those neurons die?

1, Primary (原发性) , unknown

2, secondary, chemicals: Mn2++, CO, brain injury, chemicals (除草剂、杀虫剂)…

Page 15: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

1976 美国一名大学生自己合成 MPPP (非法毒品)享用,因制备错误,得到 MPTP 。

3 天后, PD 样症状。家人误以为得精神分裂症。医生诊断后给抗帕金森病药物

2 年后自杀,尸检发现黑质损伤。

Page 16: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

1982 美国加州年轻人中发生帕金森病的爆发小流行

神经内科医生了解:

都使用过一名药剂师合成的注射用毒品 MPPP

制备毒品反应条件意外有误

含有大量的 MPTP(1-methyl-4-phenyl-1 ,2, 3, 6-tetrahydropyridine)

MPTP( 甲苯四氢吡啶)造模给猴子注射,亦得病

Page 17: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药
Page 18: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

MPTP: 1947 synthesized for anti-Parkinsonism

primates : rigid, unable to move, dies

6 persons: PD-like, 2 died.

Page 19: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

animal models

lesion of substantia nigra

MPTP model

rotenone (鱼藤酮) model

Page 21: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

                                                                                       

Page 22: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

                                                

                      

Page 23: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

ACh

DA GABA

纹状体

黑质

抗 M 胆碱

补充前体促释放

抑制降解受体激动剂

Page 24: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

提高多巴胺能神经功能 补充 DA 前体 左旋多巴 (levodopa) 促 DA 释放 金刚烷胺 (amantadine) 抑制 DA 降解 脱羧酶 卡比多巴 (carbidopa) ;

苄丝肼 (benserazide) MAO-B 司来吉林 (selegiline) COMT inhibitors 硝替卡朋 (Nitecapon

e) DA 受体激动剂 溴隐亭 (bromocriptine) 培高利 (pergolide)

降低中枢胆碱能功能 苯海索 (tribexyphenidyl)

治疗 PD 的药物

Page 25: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

左旋多巴 (Levo-dopa)

pharmacokinetics

Page 26: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

MAOCOMT

MAOBCOMT

HO

C C NH2

H

HH

H H

H

NH2CC

HO

HO

COOH

H H

HH

NH2CC

HO

HO

HO

HO

C C NH2

H

HH

HO

HO

C C

H

HH

CH2 O

HO

OH

H

H

C

HO

CH2 O COOH

COOH

L-Tyrosine

L-Dopa

Dopamine

HVA

NE

MHPG

DH

AADC

TH

Page 27: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

肝代谢 脱羧成多巴胺 DA 难通过 BBB ,进中枢 1% 同时用多巴脱羧酶抑制剂,减少外周 DA 生成 L-dopa + 卡比多巴 复方卡比多巴(信尼麦) L-dopa + 苄丝肼 多巴丝肼(美多巴) 2-4 年后逐渐失去作用

Page 28: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Side effects:

1, cardiovascular system: orthostatic (体位性) hypertension

2, nervous system:

symptoms occurred after short term use

symptoms occurred after long term (>1 year) use

Page 29: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

金刚烷胺( amantadine)

Page 30: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

amantadine (金刚烷胺)

facilitation of DA release

inhibition of DA reuptake

direct DA receptor agonistic property

weak acetylcholine antagonistic action

used for mild PD

effective only for 1-2 years

Page 31: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

bromocriptine (溴隐亭)

central D2 agonist

inhibition of prolactin (催乳素) and growth hormone secretion

Page 32: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

生长激素

促甲状腺素

促肾上腺皮质激素

促性腺激素

催乳素

黑色细胞刺激素

垂体前叶分泌的激素

Page 33: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

bromocriptineused for

PD as an adjunctive

prolactinemia (高催乳素血症) acromegaly (肢端肥大症) delactation (回乳)

Page 34: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

苯海索 trihexyphenidyl

Page 35: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

trihexyphenidyl

selective central cholinergic antagonist

used for

mild PD

intolerable to levo-dopa

no response to levo-dopa

Page 36: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Anti-dementia drugs

治疗老年性痴呆药物

Dementia

Page 37: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药
Page 38: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

1994 年 11 月 5日,美国前总统里根向公众宣布: “我最近被告知我是美国将患阿尔茨海默病的人中的一员。目前,我感觉良好。我打算在上帝赐予我的有生之年,一如既往地做我的事情。我还将和我的爱妻南希及全家一起在生命的旅途上行进。我打算多享受些野外生活的乐趣并与我的朋友和支持者们保持联系。”

    

Page 39: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

二年后 不认识熟人 六年后 不认识妻子;不知自己曾为总统 说话、做事困难 十年后 2004,died

Page 40: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

这是一种什么病?

为什么美国总统也治不好?

我们有多大机率得这种疾病?

病因、发病机制?

有什么预防、治疗的办法?

Page 41: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

What is the disease?

1906 年 德国巴伐利亚精神科医生

Alois Alzheimer描述了一名 50多岁女性

病人的临床病理学综合征,由此得名。

Page 42: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Senile plaque - Silverstaining

Page 43: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

DR. ALOIS ALZHEIMER (1864-1915)

Page 44: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

9 月 21 日 世界老年痴呆日

2005主题:行动改变未来 2006主题 : 阿尔茨海默病 100周年——关注痴呆,刻不容缓!

全世界约有痴呆患者 2400 万

2040 年 , 约 8000 万

Page 45: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

我们有多大机会得病?

>60岁 3%

>70岁 4.5~ 6%

>85岁 >20%

中国 600 万人 确诊后平均寿命 5~ 15 年

每年治疗及护理费用: 2万元

Page 46: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

痴呆原因:

变性疾病:阿尔茨海默病、帕金森病、老年性舞蹈病、肝豆状核变性

血管性疾病:多梗塞性痴呆、皮质下白质脑病

损伤:拳击家痴呆、脑外伤后、脑缺氧后、蛛网膜下腔出血、一氧化碳中毒   

感染:脑炎、脑膜炎后、克 -雅病、艾滋病

Page 47: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

中毒:酒精依赖性痴呆

肿瘤:脑瘤、慢性硬膜下血肿

代谢性疾病:维生素 B12 、叶酸缺乏、甲状腺功能低下

其他:正常颅压脑积水、癫痫、多种全身性疾病等  

Page 48: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

60多种痴呆中:

50% 阿尔茨海默病(研究原型)

30% 血管性痴呆

20% 其他类型的痴呆

Page 49: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

阿尔茨海默病成为研究重点

1~ 2 年隐性发病

95%散发性( sporadic)

<5%家族性( familial )

Page 50: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

主要症状

进行性记忆损害

认知功能障碍

行为改变:妄想、偏执、社会恰当性丧失

进行性语言功能降低

Page 51: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药
Page 52: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

早期的发现:

与学习记忆有关的胆碱能神经元显著损伤

Page 53: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

cholinesterase inhibitors

donepesil (多奈哌齐)

huperzine A (石杉碱甲)

galantamine( 加兰他敏 )

rivastigmine( 卡巴拉汀 )

Page 54: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

donepesil rivastigmine galantamine

huperzine A

Page 55: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

tacrine 他克林 not used because of hepatic toxicity

Page 56: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Evaluation:

40 ~ 50 % effective

therapeutic effect lasts about only several months ~ 1.5 years

many peripheral adverse drug reactions

Page 57: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

NMDA 阻断剂:

美金刚( memantine )

Page 58: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

previously, DA agonist

now, non-competitive NMDA antagonist→inhibit the prolonged influx of Ca2+ ions→inhibit the over-excitation of neurons caused by Aβ, one of the etiologic factors of AD lower affinity than glutamate→preserves the physiological function of the receptor

Page 59: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

1982 as an anti-Parkinson’s disease drug, but had little effect

2002 Europe approved as anti-dementia drug

Used for moderate-severe AD

美国纽约大学医学院精神病科 Reisberg:

美金刚 (memantine) 对中~重度阿尔茨海默病 (AD) 有显著长期疗效

Page 60: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

阿尔茨海默病的病理特征•细胞外 •神经炎性斑块 (neuritic plaques)•主要成分 :β-淀粉样蛋白 (-amyloid , A)

细胞内 神经纤维缠结 (neurofibrillary tangles)主要成分 : 蛋白高磷酸化使该蛋白与微管解离,形成聚集

Page 61: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

β-淀粉样蛋白产生增加

聚集成块

对神经元产生毒性

发展成 AD

形成寡聚体,损伤神经元

Page 62: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

病 理 特 征:

Page 63: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药
Page 64: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

Potential targets for the treatment of AD:

inhibitors of β,γ secretase

inhibition of Aβ production

inhibition of Aβaggression into oligomers

increase of Aβ degragation

Page 65: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

第十六章 中枢兴奋药(不作要求)

建议阅读一遍

Page 66: Chapter 15   Anti-parkinsonism and anti-dementia drugs 抗帕金森病和老年性痴呆药

建议的阅读材料 :

1, Selkoe DJ. Defining molecular targets to prevent Alzheimer disease. Arch Neurol. 2005; 62(2):192-5

2, 尹玲玲, 朱兴族 . 帕金森病的发病机制及其药物治疗研究进展。国外医学-药学分册 2006 ; 33 ( 2 ): 93-96